“o. itemList. length” “this. config. text. ariaShown”
“This. config. text. ariaFermé”
BEIJING, 17 September (Reuters) – Chinese vaccine manufacturer Sinovac Biotech plans to begin a clinical trial of its experimental coronavirus vaccine with young people and adolescents later this month, expanding its control over a vaccine already in the final stages of reading with adults. .
Finding a vaccine that works for the entire population, adding the younger ones, may be just to prevent outbreaks of the virus, which has caused more than 930,000 deaths internationally, in schools and kindergartens, which could also affect teachers and parents.
According to a registration recordhttps://bit. ly/35JkYgf published on Wednesday.
The trial has already passed through the Chinese regulator, said a spokesman for Sinovac.
China has inoculated at least tens of thousands of its citizens by deploying experimental vaccines opposed to coronaviruses, attracting foreign interest in their development, despite expert considerations on the protection of medicines that have not completed popular testing.
As a component of this program, CoronaVac, tested in large-scale final tests in Brazil, Indonesia and Turkey, has already been presented to approximately 90% of the company’s workers and their families.
Data to date recommend that the virus causes milder diseases in young people compared to adults; However, some cases of young people requiring extensive care have also been reported, according to the World Health Organization https://www. who. int/news-room/ comments/detail/inflammatory-multisystem-syndrome-in-young-and-adolescent-affected-of-covid-19.
Several hundred young people have been admitted to US hospitals. But it’s not the first time With a rare but severe inflammatory syndrome, which can present symptoms such as fever, rash and inflammation of the glands, related to the coronavirus.
Sinovac said earlier this month that CoronaVac gave the impression of being and able to induce antibodies in the elderly, while the degrees of antibodies generated through the vaccine were slightly lower than those observed in young adults, which poses the initial effects from an early phase to an intermediate. (Report through Roxanne Liu and Tony Munroe; Editing via Kenneth Maxwell)